Background: Antimicrobial resistance in long-term care facilities (LTCFs) poses a risk to elderly residents. The aim of this observational study was to investigate recent patterns of antimicrobial susceptibility in urine samples submitted to the Microbiology Laboratory at Cork University Hospital (CUH) from LTCFs in the greater Cork region. The antimicrobial susceptibilities of LTCF and General Practitioner (GP) urine samples sent to CUH, for patients aged over 65 years of age, were compared. Methods: A retrospective analysis of the antimicrobial susceptibilities of urine samples submitted to the microbiology laboratory at CUH in quarter one of 2011-2014 was conducted. LTCF and GP urine sample susceptibilities, for patients over 65 years of age, were compared using Chi square statistics. Results: Overall, the LTCF urine samples were less susceptible than GP urine samples to the antimicrobials recommended in the national urinary tract infection guidelines; trimethoprim, nitrofurantoin, cephalexin, co-amoxiclav, ciprofloxacin and amoxicillin (P < 0.001). Important trends in antimicrobial susceptibility over the time period were noted. A significant reduction in susceptibility to co-amoxiclav was found between Q1 2011 and Q1 2014 in both settings (GP P = 0.013, LTCF P = 0.005). Conclusion: This study provides important information which will contribute to the revision of antimicrobial prescribing guidelines in the future. This study highlights the need for continuous surveillance of antimicrobial susceptibility trends in LTCFs. Antimicrobial stewardship strategies are urgently required to address antimicrobial resistance and appropriate antimicrobial prescribing in the LTCF setting.
Introduction
U rinary tract infections (UTIs) are one of the leading causes of infection and antimicrobial prescribing in the Long Term Care Facility (LTCF) setting. 1 In Ireland, the Health Protection Surveillance Centre (HPSC) has produced guidelines for the Diagnosis and Management of UTI in Long-Term Care patients over 65 years. 2 In these guidelines, trimethoprim and nitrofurantoin are recommended as first line agents to treat uncomplicated UTI, cephalexin and co-amoxiclav are recommended depending on local resistance rates, and ciprofloxacin and co-amoxiclav are recommended for acute pyelonephritis. 2 In the most recent Healthcare associated infections in LTCFs point prevalence survey in Ireland (HALT, May 2013) UTIs were prevalent in 1.7% of all residents in 190 included LTCFs. 3 In order to prescribe antimicrobials empirically for UTIs in LTCFs it is important to follow recent local antimicrobial resistance patterns. The aim of this retrospective study is to investigate recent patterns of antimicrobial susceptibility in urine samples submitted to the Microbiology Laboratory at Cork University Hospital (CUH) from LTCFs in the greater Cork region. This study will also analyse the urine samples of patients aged over 65 years, sent to CUH by General Practitioners so that a comparison of LTCF and primary care urine sample susceptibility can be undertaken.
Methods
Ethical approval was sought and obtained from the Clinical Research Ethics Committee of the Cork Teaching Hospitals. The microbiology data was extracted from the laboratory of CUH and anonymised. Data from the first quarter (January-March) of each year from 2011 to 2014 were extracted. Patients aged over 65 years were selected as this is the commonly used age threshold in Central Statistics Office and Nursing Home Ireland reports to define an elderly population. 4, 5 The CUH laboratory tests for antimicrobial resistance in urine samples with visible bacteria and/or white blood cells (WBC). 6 Definitive sensitivities on isolates reported here were obtained using Clinical and Laboratory Standards Institute Õ (CLSI) guidelines for disk diffusion on agar plates. 7, 8 Mid-stream urine samples (MSU) and catheter specimen of urine samples (CSU) were included. Only samples with UTI were included for analysis and this was defined for MSUs as a pure growth of !100 000 colony forming units per ml (cfu/ml). Additionally, if the WBC count in an MSU was more than 100, a pure growth of !10 000 cfu/ml was used to define infection. The CSU samples were evaluated separately to determine if there were any differences in antimicrobial susceptibility or significant differences across the four years. For CSU samples, infection was defined as a WBC count >100 cells/mm 3 with a pure growth of !100 000 cfu/ml. Only the first positive sample per person was included where multiple samples were submitted and were positive for the same microorganism. This is standard procedure in order to reduce the bias which would result from multiple samples from the same patient and follows recommendations from the Strategy for the control of Antimicrobial Resistance in Ireland (SARI) and the European Antimicrobial Resistance Surveillance Network (EARS-NET) methodology. 9 The data were analysed using Microsoft Excel for Windows 2010 and StataCorp. The data were analysed using Microsoft Excel for Windows 2010 and Stata statistical software, release 12 (StataCorp LP, College Station, TX, USA). T tests were used to compare continuous data and Chi square statistics were conducted to compare categorical data. A significance level of P 0.05 was set. . The LTCF patients were older, had a higher proportion of female patients and a higher proportion of CSU samples than the GP patients (P < 0.001).
Results

Demographics
Antimicrobial susceptibilities
The most common bacterial family groups identified in the positive urine samples were Enterobacteriaceae (including E. coli, Proteus, Citrobacter koseri, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumonia, Multi-drug Resistant Klebsiella pneumonia, Morganella morganii and Serratia species) and Enterococcus (including Enterococcus faecalis and Enterococcus faecium). Organisms which represented very smaller proportions of the overall positive urine sample data were not included in the analysis. The antimicrobial susceptibilities of these main groups to the common antimicrobials are presented in figures 1 and 2 and Tables 1 and 2 .
When the antimicrobial susceptibility data from Q1 2014 was analysed, it was found that fewer LTCF urine samples than GP urine samples were susceptible to nitrofurantoin (P = 0.007), cephalexin (P = 0.004), co-amoxiclav (P < 0.001) and ciprofloxacin (P = 0.001); however trimethoprim and amoxicillin were not significant (P = 0.08 and 0.062, respectively). Significant differences were also found between LTCF and GP urine sample susceptibility in Q1 2013 (trimethoprim P < 0.001, nitrofurantoin P = 0.001, coamoxiclav P = 0.004, ciprofloxacin P = 0.011, amoxicillin P = 0.013). In Q1 2012, fewer LTCF samples were susceptible to the following antimicrobials; trimethoprim (P = 0.017), nitrofurantoin (P = 0.001), co-amoxiclav (P = 0.046), ciprofloxacin (P = 0.042) and amoxicillin (P < 0.001). In Q1 2011, fewer LTCF samples were susceptible to trimethoprim (P = 0.007), ciprofloxacin (P = 0.001) and amoxicillin (P = 0.021).
The Guidelines for Antimicrobial Prescribing in Primary Care in Ireland and the published guideline for the Diagnosis and Management of UTI in Long Term Care Residents >65 years recommend trimethoprim or nitrofurantoin as first line empiric antimicrobials for UTI in LTCF. 2, 10 Co-amoxiclav and cephalexin are recommended as second line options depending on local resistance rates, and ciprofloxacin is reserved for acute pyelonephritis. When the urine sample susceptibilities were collated into first line antimicrobials (trimethoprim and nitrofurantoin) and second line antimicrobials (co-amoxiclav, cephalexin and ciprofloxacin) it is seen that in Q1 2011, Q1 2012 and Q1 2013 significantly fewer LTCF urine samples than GP urine samples were susceptible to the first line antimicrobials (P 0.001 for each year). In Q1 2014 fewer LTCF urine samples were susceptible to the first line antimicrobials but the difference was not statistically significant (P = 0.119). In Q1 2011-2014 fewer GP urine samples were susceptible to the first line antimicrobials than the second line antimicrobials (P < 0.001 in Q1 of all years).
The average susceptibility to trimethoprim of LTCF urine samples (Q1 2011-2014) is 46.0% (SD = 4.54%), and of GP urine samples is 58.8% (SD = 0.975%). For each Q1 2011-2014 there were fewer LTCF urine samples than GP urine samples susceptible to trimethoprim; this was statistically significant in Q1 2011, Q1 2012 and Q1 2013 (P = 0.007, P = 0.017, P < 0.001 respectively). This is probably affected by the greater proportion of non-susceptible samples to trimethoprim in LTCF samples in these years. In 2014 52% (53/ 102) of LTCF samples were susceptible to trimethoprim. Even though the proportion was less than in GP samples (61%), the difference between the settings was not statistically significant difference (P = 0.08). The proportion of LTCF urine samples susceptible to trimethoprim increased, albeit not significantly, when Q1 2011 data and Q1 2014 data were compared (P = 0.07).
Nitrofurantoin is another first line antimicrobial recommended for UTI and the majority of LTCF urine samples (78%, SD = 4.35%) and GP urine samples (88%, SD = 1.89%) were susceptible to it. There were significant differences in urine sample susceptibility to nitrofurantoin between GP samples and LTCF samples in Q1 2012 (P = 0.001), Q1 2013 (P = 0.001) and Q1 2014 (P = 0.007). In LTCF samples the susceptibility to nitrofurantoin may be decreasing steadily but this trend was not statistically significant (Q1 2011 compared to Q1 2014 P = 0.08). In GP samples, despite a significant difference when comparing Q1 2011 and Q1 2014 (P = 0.046), the overall trend is not showing any definite pattern despite a statistically significant difference across the years (P = 0.014). .
Another antimicrobial which is commonly prescribed for UTI is cephalexin. The only time period where there was a significant difference between the GP and LTCF sample susceptibility to cephalexin was in 2014 (P = 0.004). LTCF urine sample susceptibility to cephalexin has fallen significantly when Q1 2011 and Q1 2014 data are compared (P = 0.01). GP urine sample susceptibility data have not demonstrated any consistent increase or decrease, despite changes year on year.
The decrease in urine susceptibilities to co-amoxiclav from both GP and LTCF samples is notable. In 2012 (P = 0.046), 2013 (P = 0.004) and 2014 (P < 0.001), LTCF samples were significantly less susceptible to co-amoxiclav than GP samples. A significant reduction in susceptibility was found when Q1 2011 and Q1 2014 data were compared (GP P = 0.01, LTCF P = 0.005).
The difference in susceptibility to ciprofloxacin between GP and LTCF urine samples was significant in all years (Q1 2011 P < 0.001, Q1 2012 P = 0.042, Q1 2013 P = 0.011, Q1 2014 P < 0.001). There has been a gradual increase in the proportion of LTCF urine samples susceptible to ciprofloxacin when Q1 2011 and Q1 2014 data were compared (P = 0.013). The corresponding increase in the GP samples was not significant (P = 0.061).
There was no significant change in trend in urine susceptibility to amoxicillin in LTCF samples between 2011 and 2014 (P = 0.639). In the GP urine sample data, an increase in susceptibility when Q1 2011 and Q1 2014 were compared was noted (P < 0.001). In Q1 2011, Q1 2012 and Q1 2013 the GP samples had a higher susceptibility to amoxicillin than the LTCF samples (2011 P = 0.021, 2012 P < 0.001, 2013 P = 0.013). However, the difference in 2014 was not statistically significant (P = 0.062). This antimicrobial, while tested on all microbiology urine susceptibility tests, is not listed as a first or second line antimicrobial in the UTI guidelines. 
Catheter urine sample susceptibilities
Discussion
This investigation of LTCF urine samples, and the comparison with GP samples in patients over 65 years of age, provides important information about local antimicrobial resistance rates. To our knowledge, this is the first study to investigate and compare the trends in Irish urine sample susceptibility between LTCF and GP samples over several years. The key findings highlight that, overall, the LTCF urine samples were less susceptible than GP urine samples to the antimicrobials recommended in the guidelines for UTI prescribing in primary care and LTCF. Some notable trends were identified in the data which warrant continuous monitoring over the coming years. Susceptibilities to nitrofurantoin decreased very gradually from Q1 2011 to Q1 2013 but stabilised in Q1 2014. This trend needs to be closely observed as nitrofurantoin is active against many Extended Spectrum Beta-Lactamase (ESBL) bacteria and is often an effective first line empiric agent which is recommended in many clinical practice guidelines. While its use in renally impaired patients with creatinine clearance <60 ml/min is contraindicated, it should be considered as an option for all other patients. 11 Cephalexin susceptibilities in LTCF urine samples were lowest in Q1 2014, and while not statistically significant, if this trend continues it may suggest the increasing prevalence of cephalosporin resistant infections in LTCFs. Trimethoprim susceptibility rates demonstrated a gradual increase in the LTCF samples from Q1 2011 to Q1 2014. This trend should be monitored over future years as in many regions resistance to trimethoprim is high or increasing and this is discouraging the use of this antimicrobial as a first line agent for UTI. It could be proposed that the increase in susceptibility may be related to a decrease in prescribing rates, however there is no causal evidence to link these parameters definitively.
A similar study conducted on 2010 data in the Health Service Executive Dublin North Eastern region compared LTCF and GP urine samples for 2010. 12 This study also found that overall there were higher levels of resistance to antimicrobials (co-amoxiclav, ciprofloxacin, nitrofurantoin, trimethoprim) in the LTCF urine samples compared to the GP urine samples. 12 The resistance rate of E.coli in urine samples to trimethoprim was 68% of LTCF samples and 48% of GP samples in the Dublin North East region in 2010. 12 Our data found higher susceptibility rates of the main bacterial groups (Enterobacteriaceae, Enterococcus) to trimethoprim of 41-52% in LTCF and 59% to 61% in GP populations from 2011 to 2014. A direct comparison cannot be made between the studies as the reporting of bacterial isolates to species level differs between the laboratories as well as the time period. The Antimicrobial Resistance and Use in Humans 2014 report from the National Health Service Scotland outlined resistance rates in primary care E. coli urine sample isolates. 13 On comparing the 2014 GP sample results from this study with the Scottish report it is notable that in both jurisdictions resistance to trimethoprim is high. However, in Scotland the 2014 resistance to nitrofurantoin (3.2%) and cephalexin (7.4%) was notably lower than that found in our study. A comparison of the studies must be conducted with caution as the age ranges of the included populations are different, however, antimicrobial stewardship activities in Scotland should be examined when planning future strategies in Ireland.
Recently published figures from a study investigating the treatment of UTI in general practice in the Galway region included 22 practices and found that 14% of patients had an isolate identified and were prescribed an antimicrobial to which the isolate was susceptible.
14 This study recommended that the quality of antimicrobial prescribing for UTI could be improved in terms of matching the isolate to the antimicrobial. Fennell et al. in a study investigating clinical and laboratory data, found that numbers of ESBL-producing E. coli from urine and blood cultures increased from July 2004 to December 2008. 15 Recent surveillance data published by the EARS-Net Report 2014 have indicated that E. coli infections resistant to third generation cephalosporins (ceftazidime and ceftriaxone) are increasing. 16 While cephalexin is a first generation cephalosporin, the increasing prevalence of ESBL infections is important to consider as these bacteria possess enhanced resistance against beta-lactam based antimicrobials. Nursing home patients were found to have higher rates of coresistance to other antimicrobials, especially in ESBL isolates, than hospital patients. 15 Previous antimicrobial prescriptions have been shown to contribute to the development of E. coli resistance and this has an impact on the available treatment options for UTI. 17 As our study has shown a lower susceptibility of urine pathogens to the main antimicrobials in the LTCF samples compared to GP samples, the need for appropriate antimicrobial prescribing initiatives is underlined.
The increasing prevalence of antimicrobial resistance in LTCF is an international issue. Viray et al. conducted an analysis of urine samples in four LTCFs in Pennsylvania, USA and found that significant increasing trends in antimicrobial resistance were found over time, particularly Enterobacteriaceae resistance to fluoroquinolone antimicrobials. 18 A study in five LTCFs in Connecticut, USA found that urine samples in patients with suspected UTI had a high prevalence of resistance to fluoroquinolones. 19 A study in Melbourne, Australia, analysed 4044 urine samples (783 from LTCFs, 3261 from the general community ! 65 years old) from July 2003 and June 2008. 20 Similar to our study findings, this study found that the LTCF samples had higher resistance rates to commonly prescribed antimicrobials (co-amoxiclav 27.1 versus 19.8%, trimethoprim 29.6 versus 16.2%, nitrofurantoin 22.8 versus 14.9%, ciprofloxacin 5.8 versus 3.1%), and higher rates of multidrug resistance (12.4 versus 6.1%). 20 The lessons from these results, in conjunction with those of this study, highlight the importance of urine cultures and targeted antimicrobial therapy in order to curtail the increasing prevalence of AMR in LTCFs. Over recent years the Healthcare acquired infections in Long Term care facilities (HALT) point prevalence studies have collected information on infection, antimicrobial prescribing and AMS structures in this setting. 21 While the HALT-2 report in 2013 did not collect detailed information on AMR, these studies have raised the importance of microbiological and laboratory input to support infection diagnosis in LTCFs. 18 There are several important points to take into account when interpreting the results of this study. The data represents urine samples sent for analysis when a UTI is suspected and therefore, the data do not represent an overall prevalence of antimicrobial susceptibility across the complete LTCF population or the total GP population over 65 years old. Many of the samples may be from patients with asymptomatic bacteriuria and UTI severity cannot be determined from the samples alone as the decision to submit a sample is subjective. As well as this, not all cases of UTI have a urine sample sent for microbiological testing, so this data is not representative of all cases of UTI in LTCF or GP population over 65 years old. There may be an uncertain level of catheter colonisation in the CSU samples submitted. A more comprehensive analysis may result from the analysis of data from all quarters of the years investigated. However, the SARI and EARS-Net recommendations for Antimicrobial Resistance surveillance advise that additional surveillance on laboratory data should include the first isolate per patient per quarter in order to minimise additional workload. 9 The Irish HALT study 2013 found that 33% of recorded UTIs on the day of the study were confirmed microbiologically. 3 Many samples are not identified to bacterial species level, for example E. coli and Coliforms are recorded as Enterobacteriaceae in our data. As there were fewer CSU than MSU samples, the detection of any significant trends was compromised and the results should be interpreted with caution.
The findings of this study are of relevance to many health care professionals working in the primary care and LTCF setting such as GPs, pharmacists and nurses, as well as those responsible for providing local antimicrobial prescribing guidance, such as microbiologists. Local and national dissemination of the findings is a priority. It has been reported that the availability of data regarding local antimicrobial resistance data in LTCF is variable (17% in Europe as reported by HALT 2009). 22 There is a need to collate and disseminate local antimicrobial resistance patterns to GPs and LTCFs in order to inform updates to antimicrobial prescribing guidelines and antimicrobial prescribing at a local level. This study highlights the necessity to continuously monitor and update antimicrobial susceptibility data to support evidence based decision making regarding antimicrobial stewardship in the LTCF setting. As has previously been identified by a qualitative, multidisciplinary study interviewing doctors, nurses and pharmacists, few had any insight or knowledge of local antimicrobial resistance trends or data. 23 The implementation of future Antimicrobial Stewardship Strategies (AMS) in the LTCF setting, as well as infection control and hand hygiene measures would benefit from referencing or containing summary information of the findings of this investigation.
Conclusion
The findings of this local study highlight the importance of continuously monitoring the antimicrobial susceptibility of UTI pathogens as changes in susceptibility rates can change over time. The difference between the LTCF and GP population urine susceptibilities was notable, with LTCF population urine samples being consistently less susceptible to the main antimicrobials than the GP population. These issues raised in this study must be considered when developing antimicrobial prescribing guidelines and implementing antimicrobial stewardship strategies in the LTCF setting at local and national level.
